Health ❯ Clinical Research

Drug Efficacy

Clinical Trials Side Effects Phase Trials Weight Loss Studies Weight Loss Treatments Patient Outcomes Weight Loss Medications Patient Response Cirrhosis Treatment Muscle Preservation

Oral GLP‑1 Approval and New Trials Push Weight‑Loss Drugs Into Mass Market

Pill approvals and large sales forecasts are accelerating global uptake while tightening coverage and exposing safety and long‑term care gaps.

Anvisa Expands Wegovy and Ozempic Uses to Cardiovascular and Kidney Protection

Brazil Approves Twice-Yearly Lenacapavir Injection for HIV Prevention

Zealand Pharma Unveils ‘Metabolic Frontier 2030’ With Targets for Five Launches

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

Genmab to Buy Merus for $8 Billion to Secure Petosemtamab Cancer Drug

Celebrities Put Propranolol in the Spotlight as Off-Label Anxiety Aid

Wegovy Becomes First GLP-1 Therapy Approved by FDA for MASH

WHO Recommends Six-Monthly Lenacapavir Injection for HIV Prevention

AstraZeneca’s Baxdrostat Delivers Significant Blood Pressure Reductions in Phase 3 Trial for Resistant Hypertension

Albumin-PLGA Nanoparticles Enable Ultrahigh Drug Loading and Six-Month Stability

Novo Nordisk Partners with Septerna in $2.2 Billion Deal for Oral Obesity Therapies

Novo Nordisk's Amycretin Shows 22% Weight Loss in Trial, Boosting Stock

Novo Nordisk Launches Wegovy in France Without Reimbursement